Answers are grounded in this paper and cite their sources.
Randomized controlled trial tests cangrelor on myocardial infarction size and microvascular obstruction in ST-segment-elevation myocardial infarction, suggesting potential cardioprotective benefits.
The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarction (MI) size in the preclinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction in patients with ST-segment-elevation MI undergoing primary percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Bulluck et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: